TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06225752
Drug: Placebo probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
Study: NCT05898373
Drug: vedicitumomab in combination with pyrrolizidine
Normalized name: miconazole
DrugBank: Pyrrolizidine (DB19159)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: vedicitumomab in combination with pyrrolizidine
Study: NCT05898373
Drug: RC48 in combination with a platinum-based chemotherapeutic agent
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48 in combination with a platinum-based chemotherapeutic agent
Study: NCT05898373
Drug: RC48 in combination with teraplizumab
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RC48 in combination with teraplizumab
Study: NCT05787509
Drug: Progesterone Sustained-release vaginal gel
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the treatment time of vaginal progesterone
Study: NCT05303285
Drug: Secukinumab 300mg s.c.
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
Study: NCT05303285
Drug: Secukinumab 150mg s.c.
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
Study: NCT06591091
Drug: Clemastine Fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Listed in arm/group description
Study: NCT05189197
Drug: Zanubrutinib + R-CHOP
Normalized name: Zanubrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg BID administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved CR will continue to receive zanubrutinib 160mg BID for 1 year.
Study: NCT05551221
Drug: Silodosin Capsules
Normalized name: Silodosin Capsules
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
Study: NCT05551221
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
Study: NCT05934253
Drug: Chloroprocaine ophthalmic gel 3%
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
Study: NCT06408623
Drug: chidamide combined with Sintilimab and bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chidamide combined with Sintilimab and bevacizumab
Study: NCT05540275
Drug: Tislelizumab plus Bevacizumab
Normalized name: Tislelizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
Study: NCT06588907
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After preparing the infraclavicular block site, a 22-gauge needle, guided by ultrasound, will be placed in the 6-7 o'clock position in the same plane as the ultrasound probe. Subsequently, lateral, medial, and posterior cords described as hypoechoic nerve fascicles within hyperechoic structures will be identified. Initially, 2 mL of saline will be administered to confirm proper spread. Once confirmed, 20 mL of 0.25% bupivacaine (prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline) will be injected in fractional doses with intermittent negative aspiration. Fifteen minutes after this procedure, anesthesia depth will be assessed using a cold-hot test, followed by reduction and application of the cast.
Study: NCT05210946
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
Study: NCT06005155
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained long-term exposure
Study: NCT04941911
Drug: Octreotide Acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.
Study: NCT05965934
Drug: Direct Sodium Removal Infusate 2.0
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Direct Sodium Removal via peritoneal ultrafiltration using Infusate 2.0 (30% icodextrin, 10% dextrose). Patients (if not yet on SGLT-2 inhibitors) will receive SGLT-2 inhibitors.
Study: NCT06470464
Drug: Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The oral dose of thalidomide is 1.5-2.5mg/kg/d daily (maximum 28g). Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
Study: NCT06588907
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Until the recovery period, patients will be closely monitored by an experienced doctor or nurse during sedation. Emergency equipment will be readily available in case of any complications. The following protocol will be used for procedural sedation-analgesia (PSA): Ketamine will be administered intravenously at a dose of 0.5-1 mg/kg. Patients with Numeric Rating Scale (NRS) scores above 5 may receive additional doses of 0.25-1 mg/kg, repeated every 5 to 10 minutes as needed.
Study: NCT06081062
Drug: Active comparator (Agalsidase beta)
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg every 2 weeks for 12 months
Study: NCT06245707
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dosage of rituximab depends on peripheral blood B cells. After the treatment of rituximab, the peripheral blood B cells were in a clear state and then stopped. After monitoring the recovery of B cells, additional doses were given.
Study: NCT06236997
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
Study: NCT06236997
Drug: etoposide, carboplatin(EC)
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
Study: NCT06550453
Drug: Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pabolizumab is an lgG4 subclass monoclonal antibody humanized against PD-l molecules thatblocks the immune escape mechanism of cancer cells by inhibiting the PD-l receptor oflymphocytes, thereby allowing the immune system to destroy them.~In the single-arm study, all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity.
Study: NCT06028373
Drug: ATG-031
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-031 will be infused Q3W on Day 1 of each cycle, at the starting dose of 0.03 mg/kg and a maximum dose of 9 mg/kg in the Dose Escalation Phase, and the defined MTD if available or OBD in the Dose Expansion Phase. Based on the emerging PK, PDx, safety, and other relevant data, SRC may decide to explore alternative dosing schedules.
Study: NCT04894240
Drug: Monepantel
Normalized name: Monepantel
DrugBank: Monepantel (DB18755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
Study: NCT05442931
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The oral tablet half an hour preoperative 150 milligrams
Study: NCT05442931
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous administration half an hour preoperative 2 grams
Study: NCT05442931
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: measure total dose of nitroglycerine in milligrams using a syringe pump
Study: NCT05921500
Drug: sodium peborate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internal bleaching of discolored primary anterior teeth by using sodium peborate
Study: NCT06218550
Drug: Delta-9-THC
Normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute self-administration of inhaled or oral ∆9-THC by healthy adult research volunteers
Study: NCT06218550
Drug: Delta-8-THC
Normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute self-administration of inhaled or oral ∆8-THC by healthy adult research volunteers
Study: NCT05372939
Drug: AMT-101 (oral)
Normalized name: OXT-101
DrugBank: AMT-101 (DB18555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMT 101 is orally administered biological therapeutic taken once daily
Study: NCT05796973
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication.
Study: NCT00002390
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05125978
Drug: Dipyrone
Normalized name: Dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 1 tablet twice a day
Study: NCT05125978
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol 1 coated tablet twice a day
Study: NCT06471894
Drug: FMT Protocol
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution
Study: NCT04772235
Drug: Repotrectinib
Normalized name: Repotrectinib
DrugBank: Repotrectinib (DB16826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib~Part B: at the RP2D for all patients in combination with osimertinib.
Study: NCT04772235
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted.~Part B: at the RP2D level in combination with repotrectinib
Study: NCT04798287
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Study: NCT05895500
Drug: Injection for SC administration (120mg/syringe)
Normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT05064800
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of Dabigatran on Day 1
Study: NCT05064800
Drug: PF-07321332/ritonavir + Dabigatran
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2
Study: NCT05064800
Drug: Ritonavir + Dabigatran
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
Study: NCT04909255
Drug: mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use beta-3 agonist for sjogren syndrome patient
Study: NCT04909255
Drug: oxybutynin, tolterodine, solifenacin
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use anti-muscarinic agent for patient with overactive bladder syndrome
Study: NCT06028737
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2, d1, i.v., every 2 weeks
Study: NCT06028737
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m², d1, i.v., every 2 weeks
Study: NCT05574049
Drug: Tetrahydrocannabivarin
Normalized name: Tetrahydrocannabivarin
DrugBank: Tetrahydrocannabivarin (DB11755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will take once daily oromucosal strip with intervention drug for 90 days.
Study: NCT06122545
Drug: bupivacaine or onabotulinum toxin A injection.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.
Study: NCT05730673
Drug: 700mg leronlimab weekly dose
Normalized name: selinexor
DrugBank: Leronlimab (DB05941)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5
Study: NCT05730673
Drug: 80mg Regorafenib at week 1
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib is a small-molecule multiple kinase inhibitor
Study: NCT05730673
Drug: 120mg Regorafenib at week2
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib is a small-molecule multiple kinase inhibitor
Study: NCT05730673
Drug: 160 mg Regorafenib at week 3
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib is a small-molecule multiple kinase inhibitor
Study: NCT05760586
Drug: Tovorafenib
Normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL)
Study: NCT06231121
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
Study: NCT05489055
Drug: Iopamidol
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a ﬂow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.
Study: NCT04685915
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsule, taken by mouth once daily
Study: NCT04685915
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT04685915
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule, taken by mouth twice daily
Study: NCT05855187
Drug: Bravamax 200 mg (Modafinil)
Normalized name: modafinil 200 MG
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test drug
Study: NCT05855187
Drug: Vigil 200 mg (Modafinil)
Normalized name: modafinil 200 MG
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference drug
Study: NCT04937530
Drug: RT001
Normalized name: Risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
Study: NCT05249920
Drug: Edaravone Dexborneol Concentrated Solution for injection
Normalized name: edaravone Injection
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
Study: NCT05249920
Drug: Edaravone Dexborneol placebo
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
Study: NCT04987970
Drug: CKD-386(2)
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT06420908
Drug: Adebrelimab+TP/FP+ radiation therapy
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage:~TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs.
Study: NCT06420908
Drug: Adebrelimab+FP/TP+ radiation therapy
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage: (switch to a different chemotherapy drug which not used during the earlier induction phase)~FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs.
Study: NCT05523739
Drug: STI-1558
Normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Study: NCT05082155
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.